2009, TIMACS trial: Early vs delayed invasive intervention in acute coronary syndrome, NEJM
TIMACS trial addressed the question of when to intervene in patients who come to
The ABOARD and OPTIMA trial were done during the same year but these were smaller trials with limited study population compared to TIMACS trial. The FRISC II trial (1999) also showed benefits of early intervention within 7 days in terms of
The 2014 ACC/AHA guidelines on NSTE-ACS recommends early invasive strategy (within 24 hours of admission) over a delayed invasive strategy (within 25 to 72 hours) for initially stabilized high-risk patients with NSTE-ACS.